New hope for Hard-to-Treat endometrial cancer: pfizer launches phase 3 trial

NCT ID NCT07578649

Not yet recruiting Disease control Sponsor: Pfizer Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 24, 2026 · Updated 1 time

Summary

This Phase 3 trial tests a new biologic drug (PF-08634404) plus chemotherapy against the approved drug Keytruda plus chemotherapy in 600 women with advanced or recurrent pMMR endometrial cancer. The goal is to see if the new combination helps patients live longer without their cancer worsening. Participants will be randomly assigned to one of two groups and receive treatment for up to two years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: PF-08634404 (a biologic drug) plus chemotherapy
What this could lead to: If it works, this could offer a new treatment option for people with advanced or recurrent pMMR endometrial cancer, potentially improving how long they live without the cancer growing.
What could go wrong: This is an early-stage Phase 3 trial that hasn't started recruiting yet. The new drug may not be more effective than the existing treatment (Keytruda), and side effects from combining it with chemotherapy are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ENDOMETRIAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

endometrial cancer endometrium neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ENDOMETRIAL CANCER ENDOMETRIAL NEOPLASMS

More trials for these conditions

Other studies related to the condition(s) this trial covers.